T-cell therapy for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage IIIc or IV) that cannot be surgically removed or has spread to other parts of your body.
- You have already tried a PD-1 checkpoint inhibitor (like Keytruda or Opdivo) and your cancer continued to grow.
- You are between 18 and 75 years old and in fairly good health (able to do everyday activities).
- You have at least one melanoma tumor (bigger than a sugar cube) that can be surgically removed to make the special T-cells.
- Your heart and other organs (like kidneys, liver, and blood counts) must be working well enough to handle the treatment.
- You cannot have more than 2 small, stable brain metastases; any active or large brain spots must be treated first.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.